Company Announcements

Diaceutics Announces Key Leadership Appointment

Source: RNS
RNS Number : 1382I
Diaceutics PLC
15 October 2024
 

RNS Reach

Diaceutics Announces Key Leadership Appointment

Sandra Blake appointed Chief People Officer

Belfast and London, 15 October 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, is pleased to announce the appointment of Sandra Blake as Chief People Officer of Diaceutics PLC.

Sandra has over 25 years leadership experience across Human Resources, Marketing & Innovation in the Technology, Engineering, Banking, Insurance, FMCG, Retail and Energy sectors. 

 

Sandra has worked with companies including NatWest Group PLC, Tesco PLC, Cadbury PLC and Kraft Foods Inc.

 

Ryan Keeling, Chief Execuitve Officer of Diaceutics commented: "Sandra brings a wealth of operational and management experience to the Diaceutics team and I know she will provide a significant contribution to our performance and growth in the future."

 

Sandra Blake, Chief People Officer of Diaceutics commented: "I am honoured and excited to take on the role of Chief People Officer at Diaceutics.  I have followed Diaceutics' growth in recent years and am very much looking forward to helping maximise our market opportunity by nurturing our team's growth as we continue to drive our commercial success."

 

Enquiries: 

 

Diaceutics PLC   


Ryan Keeling, Chief Executive Officer  

Nick Roberts, Chief Financial Officer 

Tel: +44 (0)28 9040 6500

investorrelations@diaceutics.com

 



Canaccord Genuity Limited (Nomad & Broker) 

Tel: +44 (0)20 7523 8000

Simon Bridges, Andrew Potts, Harry Rees


 

Alma Strategic Communications

 

Tel: +44(0)20 3405 0205 

Caroline Forde, Kinvara Verdon

 

diaceutics@almastrategic.com

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUSSBRSAURAAA